Src: Marker or actor in prostate cancer aggressiveness

Frontiers in Oncology

Volumn 4 AUG, Issue , 2014, Pages

  Vlaeminck Guillem, Virginie ^a,b   Gillet, Germain ^a   Rimokh, Ruth ^a  

^a CENTRE DE RECHERCHE EN CANCÉROLOGIE DE LYON   (France)

^b CENTRE HOSPITALIER LYON SUD   (France)

Author keywords

Aggressiveness; C Src; Epithelial to mesenchymal transition; Neuroendocrine differentiation; Prognosis; Prostate cancer; SFK family; Tyrosine kinase

Indexed keywords

4 AMINO 7 TERT BUTYL 5 (4 CHLOROPHENYL) PYRAZOLO [3, 4 D] PYRIMIDINE; 4 AMINO 7 TERT BUTYL 5 (4 CHLOROPHENYL)PYRAZOLO[3,4 D]PYRIMIDINE; 6 (2, 6 DICHLOROPHENYL) 8 METHYL 2 (3 METHYLTHIOANILINO) 8H PYRIDO [2, 3 D] PYRIMIDIN 7 ONE; 6 (2,6 DICHLOROPHENYL) 8 METHYL 2 (3 METHYLTHIOANILINO) 8H PYRIDO[2,3 D]PYRIMIDIN 7 ONE; BMSS 354825; BOSUTINIB; DASATINIB; DOCETAXEL; FIBROBLAST GROWTH FACTOR 10; NERVE CELL ADHESION MOLECULE; PREDNISOLONE; PROTEIN TYROSINE KINASE; RESVERATROL; SARACATINIB; UNCLASSIFIED DRUG; UVOMORULIN;

AGGRESSIVENESS; ANGIOGENESIS; CANCER GROWTH; EPITHELIAL MESENCHYMAL TRANSITION; GENE OVEREXPRESSION; HUMAN; LIFE EXPECTANCY; NONHUMAN; ONCOGENE SRC; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PROSTATE CANCER; PROSTATIC INTRAEPITHELIAL NEOPLASIA; PROTEIN PHOSPHORYLATION; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SIGNAL TRANSDUCTION; TUMOR GROWTH;

EID: 84906275179     PISSN: None     EISSN: 2234943X     Source Type: Journal    
DOI: 10.3389/fonc.2014.00222     Document Type: Review

References (110)

1. Creighton CJ. Multiple oncogenic pathway signatures show coordinate expression patterns in human prostate tumors. PLoS One (2008) 3:e1816. doi: 10.1371/journal.pone.0001816
2. Tatarov O, Mitchell TJ, Seywright M, Leung HY, Brunton VG, Edwards J. SRC family kinase activity is up-regulated in hormone-refractory prostate cancer. Clin Cancer Res (2009) 15:3540-9. doi:10.1158/1078-0432.CCR-08-1857
3. Drake JM, Graham NA, Stoyanova T, Sedghi A, Goldstein AS, Cai H, et al. Oncogene-specific activation of tyrosine kinase networks during prostate cancer progression. Proc Natl Acad Sci U S A (2012) 109:1643-8. doi:10.1073/pnas.1120985109
4. Robinson D, He F, Pretlow T, Kung HJ. A tyrosine kinase profile of prostate carcinoma. Proc Natl Acad Sci U S A (1996) 93:5958-62. doi:10.1073/pnas.93.12.5958
5. Goldenberg-Furmanov M, Stein I, Pikarsky E, Rubin H, Kasem S, Wygoda M, et al. Lyn is a target gene for prostate cancer: sequence-based inhibition induces regression of human tumor xenografts. Cancer Res (2004) 64:1058-66. doi:10.1158/0008-5472.CAN-03-2420
6. Nam S, Kim D, Cheng JQ, Zhang S, Lee JH, Buettner R, et al. Action of the Src family kinase inhibitor, dasatinib (BMS-354825), on human prostate cancer cells. Cancer Res (2005) 65:9185-9. doi:10.1158/0008-5472.CAN-05-1731
7. Chang YM, Kung HJ, Evans CP. Nonreceptor tyrosine kinases in prostate cancer. Neoplasia (2007) 9:90-100. doi:10.1593/neo.06694
8. Asim M, Siddiqui IA, Hafeez BB, Baniahmad A, Mukhtar H. Src kinase potentiates androgen receptor transactivation function and invasion of androgen-independent prostate cancer C4-2 cells. Oncogene (2008) 27:3596-604. doi:10.1038/sj.onc.1211016
9. Chang YM, Bai L, Liu S, Yang JC, Kung HJ, Evans CP. Src family kinase oncogenic potential and pathways in prostate cancer as revealed by AZD0530. Oncogene (2008) 27:6365-75. doi:10.1038/onc.2008.250
10. Derry JJ, Prins GS, Ray V, Tyner AL. Altered localization and activity of the intracellular tyrosine kinase BRK/Sik in prostate tumor cells. Oncogene (2003) 22:4212-20. doi:10.1038/sj.onc.1206465
11. Wang S, Gao J, Lei Q, Rozengurt N, Pritchard C, Jiao J, et al. Prostate-specific deletion of the murine Pten tumor suppressor gene leads to metastatic prostate cancer. Cancer Cell (2003) 4:209-21. doi:10.1016/S1535-6108(03)00215-0
12. Zong Y, Xin L, Goldstein AS, Lawson DA, Teitell MA, Witte ON. ETS family transcription factors collaborate with alternative signaling pathways to induce carcinoma from adult murine prostate cells. Proc Natl Acad Sci U S A (2009) 106:12465-70. doi:10.1073/pnas.0905931106
13. Han G, Buchanan G, Ittmann M, Harris JM, Yu X, Demayo FJ, et al. Mutation of the androgen receptor causes oncogenic transformation of the prostate. Proc Natl Acad Sci U S A (2005) 102:1151-6. doi:10.1073/pnas.0408925102
14. Xin L, Teitell MA, Lawson DA, Kwon A, MellinghoffIK, Witte ON. Progression of prostate cancer by synergy of AKT with genotropic and nongenotropic actions of the androgen receptor. Proc Natl Acad Sci U S A (2006) 103:7789-94. doi:10.1073/pnas.0602567103
15. Memarzadeh S, Xin L, Mulholland DJ, Mansukhani A, Wu H, Teitell MA, et al. Enhanced paracrine FGF10 expression promotes formation of multifocal prostate adenocarcinoma and an increase in epithelial androgen receptor. Cancer Cell (2007) 12:572-85. doi:10.1016/j.ccr.2007.11.002
16. Memarzadeh S, Cai H, Janzen DM, Xin L, Lukacs R, Riedinger M, et al. Role of autonomous androgen receptor signaling in prostate cancer initiation is dichotomous and depends on the oncogenic signal. Proc Natl Acad Sci U S A (2011) 108:7962-7. doi:10.1073/pnas.1105243108
17. Cai H, Babic I, Wei X, Huang J, Witte ON. Invasive prostate carcinoma driven by c-Src and androgen receptor synergy. Cancer Res (2011) 71:862-72. doi:10.1158/0008-5472.CAN-10-1605
18. Cai H, Smith DA, Memarzadeh S, Lowell CA, Cooper JA, Witte ON. Differential transformation capacity of Src family kinases during the initiation of prostate cancer. Proc Natl Acad Sci U S A (2011) 108:6579-84. doi:10.1073/pnas.1103904108
19. Migliaccio A, Castoria G, Di Domenico M, De Falco A, Bilancio A, Lombardi M, et al. Steroid-induced androgen receptor-oestradiol receptor beta-Src complex triggers prostate cancer cell proliferation. EMBO J (2000) 19:5406-17. doi:10.1093/emboj/19.20.5406
20. Migliaccio A, Castoria G, Di Domenico M, De Falco A, Bilancio A, Lombardi M, et al. Sex steroid hormones act as growth factors. J Steroid Biochem Mol Biol (2002) 83:31-5. doi:10.1016/S0960-0760(02)00264-9
21. Guo Z, Dai B, Jiang T, Xu K, Xie Y, Kim O, et al. Regulation of androgen receptor activity by tyrosine phosphorylation. Cancer Cell (2006) 10:309-19. doi:10.1016/j.ccr.2006.08.021
22. Kraus S, Gioeli D, Vomastek T, Gordon V, Weber MJ. Receptor for activated C kinase 1 (RACK1) and Src regulate the tyrosine phosphorylation and function of the androgen receptor. Cancer Res (2006) 66:11047-54. doi:10.1158/0008-5472.CAN-06-0596
23. Zhoul J, Hernandez G, Tu SW, Huang CL, Tseng CP, Hsieh JT. The role of DOC-2/DAB2 in modulating androgen receptor-mediated cell growth via the nongenomic c-Src-mediated pathway in normal prostatic epithelium and cancer. Cancer Res (2005) 65:9906-13. doi:10.1158/0008-5472.CAN-05-1481
24. Wu K, Liu J, Tseng SF, Gore C, Ning Z, SharifiN, et al. The role of DAB2IP in androgen receptor activation during prostate cancer progression. Oncogene (2014) 33:1954-63. doi:10.1038/onc.2013.143
25. Kao CJ, Martiniez A, Shi XB, Yang J, Evans CP, Dobi A, et al. miR-30 as a tumor suppressor connects EGF/Src signal to ERG and EMT. Oncogene (2013) 33(19):2495-503. doi:10.1038/onc.2013.200
26. Lee LF, Guan J, Qiu Y, Kung HJ. Neuropeptide-induced androgen independence in prostate cancer cells: roles of nonreceptor tyrosine kinases Etk/Bmx, Src, and focal adhesion kinase. Mol Cell Biol (2001) 21:8385-97. doi:10.1128/MCB.21.24.8385-8397.2001
27. Amorino GP, Deeble PD, Parsons SJ. Neurotensin stimulates mitogenesis of prostate cancer cells through a novel c-Src/Stat5b pathway. Oncogene (2007) 26:745-56. doi:10.1038/sj.onc.1209814
28. DaSilva JO, Amorino GP, Casarez EV, Pemberton B, Parsons SJ. Neuroendocrine-derived peptides promote prostate cancer cell survival through activation of IGF-1R signaling. Prostate (2013) 73:801-12. doi:10.1002/pros.22624
29. Giannoni E, Fiaschi T, Ramponi G, Chiarugi P. Redox regulation of anoikis resistance of metastatic prostate cancer cells: key role for Src and EGFR-mediated pro-survival signals. Oncogene (2009) 28:2074-86. doi:10.1038/onc.2009.77
30. Lee LF, Louie MC, Desai SJ, Yang J, Chen HW, Evans CP, et al. Interleukin-8 confers androgen-independent growth and migration of LNCaP: differential effects of tyrosine kinases Src and FAK. Oncogene (2004) 23:2197-205. doi:10.1038/sj.onc.1207344
31. Araki S, Omori Y, Lyn D, Singh RK, Meinbach DM, Sandman Y, et al. Interleukin-8 is a molecular determinant of androgen independence and progression in prostate cancer. Cancer Res (2007) 67:6854-62. doi:10.1158/0008-5472.CAN-07-1162
32. Angelucci A, Schenone S, Gravina GL, Muzi P, Festuccia C, Vicentini C, et al. Pyrazolo[3,4-d]pyrimidines c-Src inhibitors reduce epidermal growth factor-induced migration in prostate cancer cells. Eur J Cancer (2006) 42:2838-45. doi:10.1016/j.ejca.2006.06.024
33. Varkaris A, Gaur S, Parikh NU, Song JH, Dayyani F, Jin JK, et al. Ligand-independent activation of MET through IGF-1/IGF-1R signaling. Int J Cancer (2013) 133:1536-46. doi:10.1002/ijc.28169
34. Inoue S, Branch CD, Gallick GE, Chada S, Ramesh R. Inhibition of Src kinase activity by Ad-mda7 suppresses vascular endothelial growth factor expression in prostate carcinoma cells. Mol Ther (2005) 12:707-15. doi:10.1016/j.ymthe.2005.05.015
35. Pang X, Zhang L, Lai L, Chen J, Wu Y, Yi Z, et al. 1'-Acetoxychavicol acetate suppresses angiogenesis-mediated human prostate tumor growth by targeting VEGF-mediated Src-FAK-Rho GTPase-signaling pathway. Carcinogenesis (2011) 32:904-12. doi:10.1093/carcin/bgr052
36. Slack JK, Adams RB, Rovin JD, Bissonette EA, Stoker CE, Parsons JT. Alterations in the focal adhesion kinase/Src signal transduction pathway correlate with increased migratory capacity of prostate carcinoma cells. Oncogene (2001) 20:1152-63. doi:10.1038/sj.onc.1204208
37. Summy JM, Gallick GE. Src family kinases in tumor progression and metastasis. Cancer Metastasis Rev (2003) 22:337-58. doi:10.1023/A:1023772912750
38. Kim LC, Song L, Haura EB. Src kinases as therapeutic targets for cancer. Nat Rev Clin Oncol (2009) 6:587-95. doi:10.1038/nrclinonc.2009.129
39. Guarino M. Src signaling in cancer invasion. J Cell Physiol (2010) 223:14-26. doi:10.1002/jcp.22011
40. Ishizawar R, Parsons SJ. c-Src and cooperating partners in human cancer. Cancer Cell (2004) 6:209-14. doi:10.1016/j.ccr.2004.09.001
41. Playford MP, Schaller MD. The interplay between Src and integrins in normal and tumor biology. Oncogene (2004) 23:7928-46. doi:10.1038/sj.onc.1208080
42. Edwards J. Src kinase inhibitors: an emerging therapeutic treatment option for prostate cancer. Expert Opin Investig Drugs (2010) 19:605-14. doi:10.1517/13543781003789388
43. Park SI, Zhang J, Phillips KA, Araujo JC, Najjar AM, Volgin AY, et al. Targeting SRC family kinases inhibits growth and lymph node metastases of prostate cancer in an orthotopic nude mouse model. Cancer Res (2008) 68:3323-33. doi:10.1158/0008-5472.CAN-07-2997
44. Su B, Gillard B, Gao L, Eng KH, Gelman IH. Src controls castration recurrence of CWR22 prostate cancer xenografts. Cancer Med (2013) 2:784-92. doi:10.1002/cam4.144
45. Moasser MM, Srethapakdi M, Sachar KS, Kraker AJ, Rosen N. Inhibition of Src kinases by a selective tyrosine kinase inhibitor causes mitotic arrest. Cancer Res (1999) 59:6145-52.
46. Recchia I, Rucci N, Festuccia C, Bologna M, Mackay AR, Migliaccio S, et al. Pyrrolopyrimidine c-Src inhibitors reduce growth, adhesion, motility and invasion of prostate cancer cells in vitro. Eur J Cancer (2003) 39:1927-35. doi:10.1016/S0959-8049(03)00394-0
47. Lombardo LJ, Lee FY, Chen P, Norris D, Barrish JC, Behnia K, et al. Discovery of N-(2-chloro-6-methyl- phenyl)-2-(6-(4-(2-hydroxyethyl)- piperazin-1-yl)-2-methylpyrimidin-4-ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays. J Med Chem (2004) 47:6658-61. doi:10.1021/jm049486a
48. Kotha A, Sekharam M, Cilenti L, Siddiquee K, Khaled A, Zervos AS, et al. Resveratrol inhibits Src and Stat3 signaling and induces the apoptosis of malignant cells containing activated Stat3 protein. Mol Cancer Ther (2006) 5:621-9. doi:10.1158/1535-7163.MCT-05-0268
49. Rabbani SA, Valentino ML, Arakelian A, Ali S, Boschelli F. SKI-606 (bosutinib) blocks prostate cancer invasion, growth, and metastasis in vitro and in vivo through regulation of genes involved in cancer growth and skeletal metastasis. Mol Cancer Ther (2010) 9:1147-57. doi:10.1158/1535-7163.MCT-09-0962
50. Rice L, Lepler S, Pampo C, Siemann DW. Impact of the SRC inhibitor dasatinib on the metastatic phenotype of human prostate cancer cells. Clin Exp Metastasis (2012) 29:133-42. doi:10.1007/s10585-011-9436-2
51. Guo W, Liu R, Bhardwaj G, Ma AH, Changou C, Yang JC, et al. CTA095, a novel Etk and Src dual inhibitor, induces apoptosis in prostate cancer cells and overcomes resistance to Src inhibitors. PLoS One (2013) 8:e70910. doi:10.1371/journal.pone.0070910
52. Gray MJ, Zhang J, Ellis LM, Semenza GL, Evans DB, Watowich SS, et al. HIF-1alpha, STAT3, CBP/p300 and Ref-1/APE are components of a transcriptional complex that regulates Src-dependent hypoxia-induced expression of VEGF in pancreatic and prostate carcinomas. Oncogene (2005) 24:3110-20. doi:10.1038/sj.onc.1208513
53. Yi T, Yi Z, Cho SG, Luo J, Pandey MK, Aggarwal BB, et al. Gambogic acid inhibits angiogenesis and prostate tumor growth by suppressing vascular endothelial growth factor receptor 2 signaling. Cancer Res (2008) 68:1843-50. doi:10.1158/0008-5472.CAN-07-5944
54. Pang X, Yi Z, Zhang X, Sung B, Qu W, Lian X, et al. Acetyl-11-keto-beta-boswellic acid inhibits prostate tumor growth by suppressing vascular endothelial growth factor receptor 2-mediated angiogenesis. Cancer Res (2009) 69:5893-900. doi:10.1158/0008-5472.CAN-09-0755
55. Pang X, Wu Y, Wu Y, Lu B, Chen J, Wang J, et al. (-)-Gossypol suppresses the growth of human prostate cancer xenografts via modulating VEGF signaling-mediated angiogenesis. Mol Cancer Ther (2011) 10:795-805. doi:10.1158/1535-7163.MCT-10-0936
56. Wu Y, He L, Zhang L, Chen J, Yi Z, Zhang J, et al. Anacardic acid (6-pentadecylsalicylic acid) inhibits tumor angiogenesis by targeting Src/FAK/Rho GTPases signaling pathway. J Pharmacol Exp Ther (2011) 339:403-11. doi:10.1124/jpet.111.181891
57. Mirzoeva S, Franzen CA, Pelling JC. Apigenin inhibits TGF-beta-induced VEGF expression in human prostate carcinoma cells via a Smad2/3-and Src-dependent mechanism. Mol Carcinog (2013) 53(8):598-609. doi:10.1002/mc.22005
58. Saraswati S, Kumar S, Alhaider AA. Alpha-santalol inhibits the angiogenesis and growth of human prostate tumor growth by targeting vascular endothelial growth factor receptor 2-mediated AKT/mTOR/P70S6K signaling pathway. Mol Cancer (2013) 12:147. doi:10.1186/1476-4598-12-147
59. Nauseef JT, Henry MD. Epithelial-to-mesenchymal transition in prostate cancer: paradigm or puzzle? Nat Rev Urol (2011) 8:428-39. doi:10.1038/nrurol.2011.85
60. Yang J, Weinberg RA. Epithelial-mesenchymal transition: at the crossroads of development and tumor metastasis. Dev Cell (2008) 14:818-29. doi:10.1016/j.devcel.2008.05.009
61. Thiery JP, Acloque H, Huang RY, Nieto MA. Epithelial-mesenchymal transitions in development and disease. Cell (2009) 139:871-90. doi:10.1016/j.cell.2009.11.007
62. Brabletz T, Jung A, Reu S, Porzner M, Hlubek F, Kunz-Schughart LA, et al. Variable beta-catenin expression in colorectal cancers indicates tumor progression driven by the tumor environment. Proc Natl Acad Sci U S A (2001) 98:10356-61. doi:10.1073/pnas.171610498
63. Fodde R, Brabletz T. Wnt/beta-catenin signaling in cancer stemness and malignant behavior. Curr Opin Cell Biol (2007) 19:150-8. doi:10.1016/j.ceb.2007.02.007
64. Fujita Y, Krause G, Scheffner M, Zechner D, Leddy HE, Behrens J, et al. Hakai, a c-Cbl-like protein, ubiquitinates and induces endocytosis of the E-cadherin complex. Nat Cell Biol (2002) 4:222-31. doi:10.1038/ncb758
65. Deep G, Gangar SC, Agarwal C, Agarwal R. Role of E-cadherin in antimigratory and antiinvasive efficacy of silibinin in prostate cancer cells. Cancer Prev Res (Phila) (2011) 4:1222-32. doi:10.1158/1940-6207.CAPR-10-0370
66. Putzke AP, Ventura AP, Bailey AM, Akture C, Opoku-Ansah J, Celiktas M, et al. Metastatic progression of prostate cancer and e-cadherin regulation by zeb1 and SRC family kinases. Am J Pathol (2011) 179:400-10. doi:10.1016/j.ajpath.2011.03.028
67. Majid S, Dar AA, Saini S, Arora S, Shahryari V, Zaman MS, et al. miR-23b represses proto-oncogene Src kinase and functions as methylation-silenced tumor suppressor with diagnostic and prognostic significance in prostate cancer. Cancer Res (2012) 72:6435-46. doi:10.1158/0008-5472.CAN-12-2181
68. Wei J, Xu G, Wu M, Zhang Y, Li Q, Liu P, et al. Overexpression of vimentin contributes to prostate cancer invasion and metastasis via src regulation. Anticancer Res (2008) 28:327-34.
69. Deep G, Jain AK, Ramteke A, Ting H, Vijendra KC, Gangar SC, et al. SNAI1 is critical for the aggressiveness of prostate cancer cells with low E-cadherin. Mol Cancer (2014) 13:37. doi:10.1186/1476-4598-13-37
70. Diamantopoulou Z, Kitsou P, Menashi S, Courty J, Katsoris P. Loss of receptor protein tyrosine phosphatase beta/zeta (RPTPbeta/zeta) promotes prostate cancer metastasis. J Biol Chem (2012) 287:40339-49. doi:10.1074/jbc. M112.405852
71. Bitting RL, Schaeffer D, Somarelli JA, Garcia-Blanco MA, Armstrong AJ. The role of epithelial plasticity in prostate cancer dissemination and treatment resistance. Cancer Metastasis Rev (2014) 33(2-3):441-68. doi:10.1007/s10555-013-9483-z
72. Yuan TC, Veeramani S, Lin MF. Neuroendocrine-like prostate cancer cells: neuroendocrine transdifferentiation of prostate adenocarcinoma cells. Endocr Relat Cancer (2007) 14:531-47. doi:10.1677/ERC-07-0061
73. Sun Y, Niu J, Huang J. Neuroendocrine differentiation in prostate cancer. Am J Transl Res (2009) 1:148-62.
74. Koeneman KS, Yeung F, Chung LW. Osteomimetic properties of prostate cancer cells: a hypothesis supporting the predilection of prostate cancer metastasis and growth in the bone environment. Prostate (1999) 39:246-61. doi:10.1002/(SICI)1097-0045(19990601)39:4<246::AID-PROS5>3.0.CO;2-U
75. Hagberg Thulin M, Jennbacken K, Damber JE, Welen K. Osteoblasts stimulate the osteogenic and metastatic progression of castration-resistant prostate cancer in a novel model for in vitro and in vivo studies. Clin Exp Metastasis (2014) 31:269-83. doi:10.1007/s10585-013-9626-1
76. Odero-Marah VA, Wang R, Chu G, Zayzafoon M, Xu J, Shi C, et al. Receptor activator of NF-kappaB Ligand (RANKL) expression is associated with epithelial to mesenchymal transition in human prostate cancer cells. Cell Res (2008) 18:858-70. doi:10.1038/cr.2008.84
77. Zhau HE, Odero-Marah V, Lue HW, Nomura T, Wang R, Chu G, et al. Epithelial to mesenchymal transition (EMT) in human prostate cancer: lessons learned from ARCaP model. Clin Exp Metastasis (2008) 25:601-10. doi:10.1007/s10585-008-9183-1
78. Saad F, Lipton A. SRC kinase inhibition: targeting bone metastases and tumor growth in prostate and breast cancer. Cancer Treat Rev (2010) 36:177-84. doi:10.1016/j.ctrv.2009.11.005
79. Araujo JC, Poblenz A, Corn P, Parikh NU, Starbuck MW, Thompson JT, et al. Dasatinib inhibits both osteoclast activation and prostate cancer PC-3-cell-induced osteoclast formation. Cancer Biol Ther (2009) 8:2153-9. doi:10.4161/cbt.8.22.9770
80. Koreckij T, Nguyen H, Brown LG, Yu EY, Vessella RL, Corey E. Dasatinib inhibits the growth of prostate cancer in bone and provides additional protection from osteolysis. Br J Cancer (2009) 101:263-8. doi:10.1038/sj.bjc.6605178
81. Lee YC, Huang CF, Murshed M, Chu K, Araujo JC, Ye X, et al. Src family kinase/abl inhibitor dasatinib suppresses proliferation and enhances differentiation of osteoblasts. Oncogene (2010) 29:3196-207. doi:10.1038/onc.2010.73
82. Yang JC, Bai L, Yap S, Gao AC, Kung HJ, Evans CP. Effect of the specific Src family kinase inhibitor saracatinib on osteolytic lesions using the PC-3 bone model. Mol Cancer Ther (2010) 9:1629-37. doi:10.1158/1535-7163.MCT-09-1058
83. Kim MP, Park SI, Kopetz S, Gallick GE. Src family kinases as mediators of endothelial permeability: effects on inflammation and metastasis. Cell Tissue Res (2009) 335:249-59. doi:10.1007/s00441-008-0682-9
84. Gu L, Vogiatzi P, Puhr M, Dagvadorj A, Lutz J, Ryder A, et al. Stat5 promotes metastatic behavior of human prostate cancer cells in vitro and in vivo. Endocr Relat Cancer (2010) 17:481-93. doi:10.1677/ERC-09-0328
85. Feldman BJ, Feldman D. The development of androgen-independent prostate cancer. Nat Rev Cancer (2001) 1:34-45. doi:10.1038/35094009
86. Pandini G, Mineo R, Frasca F, Roberts CT Jr, Marcelli M, Vigneri R, et al. Androgens up-regulate the insulin-like growth factor-I receptor in prostate cancer cells. Cancer Res (2005) 65:1849-57. doi:10.1158/0008-5472.CAN-04-1837
87. Culig Z, Hobisch A, Cronauer MV, Radmayr C, Trapman J, Hittmair A, et al. Androgen receptor activation in prostatic tumor cell lines by insulin-like growth factor-I, keratinocyte growth factor, and epidermal growth factor. Cancer Res (1994) 54:5474-8.
88. Gioeli D, Ficarro SB, Kwiek JJ, Aaronson D, Hancock M, Catling AD, et al. Androgen receptor phosphorylation. Regulation and identification of the phosphorylation sites. J Biol Chem (2002) 277:29304-14. doi:10.1074/jbc. M204131200
89. Heinlein CA, Chang C. Androgen receptor in prostate cancer. Endocr Rev (2004) 25:276-308. doi:10.1210/er.2002-0032
90. Desai SJ, Ma AH, Tepper CG, Chen HW, Kung HJ. Inappropriate activation of the androgen receptor by nonsteroids: involvement of the Src kinase pathway and its therapeutic implications. Cancer Res (2006) 66:10449-59. doi:10.1158/0008-5472.CAN-06-2582
91. Liu Y, Karaca M, Zhang Z, Gioeli D, Earp HS, Whang YE. Dasatinib inhibits site-specific tyrosine phosphorylation of androgen receptor by Ack1 and Src kinases. Oncogene (2010) 29:3208-16. doi:10.1038/onc.2010.103
92. Asim M, Hafeez BB, Siddiqui IA, Gerlach C, Patz M, Mukhtar H, et al. Ligand-dependent corepressor acts as a novel androgen receptor corepressor, inhibits prostate cancer growth, and is functionally inactivated by the Src protein kinase. J Biol Chem (2011) 286:37108-17. doi:10.1074/jbc. M111.292771
93. Migliaccio A, Di Domenico M, Castoria G, Nanayakkara M, Lombardi M, De Falco A, et al. Steroid receptor regulation of epidermal growth factor signaling through Src in breast and prostate cancer cells: steroid antagonist action. Cancer Res (2005) 65:10585-93. doi:10.1158/0008-5472.CAN-05-0912
94. Hitosugi T, Sasaki K, Sato M, Suzuki Y, Umezawa Y. Epidermal growth factor directs sex-specific steroid signaling through Src activation. J Biol Chem (2007) 282:10697-706. doi:10.1074/jbc. M610444200
95. Tatarov O, Edwards J. The role of SRC family kinases in prostate cancer. Transl Oncogenomics (2007) 2:67-77.
96. Yang X, Guo Z, Sun F, Li W, Alfano A, Shimelis H, et al. Novel membrane-associated androgen receptor splice variant potentiates proliferative and survival responses in prostate cancer cells. J Biol Chem (2011) 286:36152-60. doi:10.1074/jbc. M111.265124
97. DaSilva J, Gioeli D, Weber MJ, Parsons SJ. The neuroendocrine-derived peptide parathyroid hormone-related protein promotes prostate cancer cell growth by stabilizing the androgen receptor. Cancer Res (2009) 69:7402-11. doi:10.1158/0008-5472.CAN-08-4687
98. Yang JC, Ok JH, Busby JE, Borowsky AD, Kung HJ, Evans CP. Aberrant activation of androgen receptor in a new neuropeptide-autocrine model of androgen-insensitive prostate cancer. Cancer Res (2009) 69:151-60. doi:10.1158/0008-5472.CAN-08-0442
99. Gong J, Zhu J, Goodman OB Jr, Pestell RG, Schlegel PN, Nanus DM, et al. Activation of p300 histone acetyltransferase activity and acetylation of the androgen receptor by bombesin in prostate cancer cells. Oncogene (2006) 25:2011-21. doi:10.1038/sj.onc.1209231
100. Lara PN Jr, Longmate J, Evans CP, Quinn DI, Twardowski P, Chatta G, et al. A phase II trial of the Src-kinase inhibitor AZD0530 in patients with advanced castration-resistant prostate cancer: a California Cancer Consortium Study. Anticancer Drugs (2009) 20:179-84. doi:10.1097/CAD.0b013e328325a867
101. Antonarakis ES, Heath EI, Posadas EM, Yu EY, Harrison MR, Bruce JY, et al. A phase 2 study of KX2-391, an oral inhibitor of Src kinase and tubulin polymerization, in men with bone-metastatic castration-resistant prostate cancer. Cancer Chemother Pharmacol (2013) 71:883-92. doi:10.1007/s00280-013-2079-z
102. Yu EY, Wilding G, Posadas E, Gross M, Culine S, Massard C, et al. Phase II study of dasatinib in patients with metastatic castration-resistant prostate cancer. Clin Cancer Res (2009) 15:7421-8. doi:10.1158/1078-0432.CCR-09-1691
103. Yu EY, Massard C, Gross ME, Carducci MA, Culine S, Hudes G, et al. Once-daily dasatinib: expansion of phase II study evaluating safety and efficacy of dasatinib in patients with metastatic castration-resistant prostate cancer. Urology (2011) 77:1166-71. doi:10.1016/j.urology.2011.01.006
104. Twardowski PW, Beumer JH, Chen CS, Kraft AS, Chatta GS, Mitsuhashi M, et al. A phase II trial of dasatinib in patients with metastatic castration-resistant prostate cancer treated previously with chemotherapy. Anticancer Drugs (2013) 24:743-53. doi:10.1097/CAD.0b013e328361feb0
105. Araujo JC, Mathew P, Armstrong AJ, Braud EL, Posadas E, Lonberg M, et al. Dasatinib combined with docetaxel for castration-resistant prostate cancer: results from a phase 1-2 study. Cancer (2012) 118:63-71. doi:10.1002/cncr.26204
106. Araujo JC, Trudel GC, Paliwal P. Long-term use of dasatinib in patients with metastatic castration-resistant prostate cancer after receiving the combination of dasatinib and docetaxel. Cancer Manag Res (2013) 6:25-30. doi:10.2147/CMAR.S41667
107. Araujo JC, Trudel GC, Saad F, Armstrong AJ, Yu EY, Bellmunt J, et al. Docetaxel and dasatinib or placebo in men with metastatic castration-resistant prostate cancer (READY): a randomised, double-blind phase 3 trial. Lancet Oncol (2013) 14:1307-16. doi:10.1016/S1470-2045(13)70479-0
108. Lara PN Jr, Evans CP. Dasatinib and docetaxel in advanced prostate cancer. Lancet Oncol (2013) 14:1248-9. doi:10.1016/S1470-2045(13)70500-X
109. Leveque D. Pharmacokinetic interactions of dasatinib and docetaxel. Lancet Oncol (2014) 15:e51. doi:10.1016/S1470-2045(14)70004-X
110. Spreafico A, Chi KN, Sridhar SS, Smith DC, Carducci MA, Kavsak P, et al. A randomized phase II study of cediranib alone versus cediranib in combination with dasatinib in docetaxel resistant, castration resistant prostate cancer patients. Invest New Drugs (2014). doi:10.1007/s10637-014-0106-5